Controversies related to renal artery denervation and devices

Department

Internal Medicine

Document Type

Article

Publication Title

Current Opinion in Cardiology

Abstract

PURPOSE OF REVIEW: This review article discusses the controversies, strengths, and limitations of the current literature on renal artery denervation in the management of resistant hypertension, as well as the future directions of this intervention.

RECENT FINDINGS: There have been conflicting data from the different randomized control trials assessing the efficacy of renal artery denervation in the management of resistant hypertension.

SUMMARY: Renal artery denervation is achieved by ablating the sympathetic nerves surrounding the renal arteries using endovascular ultrasound, radiofrequency, or alcohol. Our review article highlights that renal artery denervation is generally effective in improving blood pressure in patients with resistant hypertension. The Food and Drug Administration (FDA) has recently approved the ReCor Medical Paradise system, and the Symplicity Spyral RDN systems for renal artery denervation.

First Page

244

Last Page

250

DOI

10.1097/HCO.0000000000001146

Volume

39

Issue

4

Publication Date

7-1-2024

Medical Subject Headings

Humans; Renal Artery (innervation); Sympathectomy (methods); Hypertension (surgery); Catheter Ablation (methods); Blood Pressure (physiology)

PubMed ID

38567924

Link to Full Text

Share

COinS